Pfizer Shells Out up to $6 Billion for Bispecific Antibody Free

Pfizer will acquire SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from the Chinese biopharmaceutical company 3SBio for $1.25 billion upfront and $4.8 billion more for meeting certain milestones. SSGJ-707 is under investigation in several Chinese phase II trials for non–small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. 3SBio plans to initiate the first phase III study of SSGJ-707 in China this year and, as per the terms of the deal, will retain full rights to the drug candidate in the country.